Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Spotlight on fulvestrant in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy

Spotlight on fulvestrant in hormone receptor-positive metastatic breast cancer in postmenopausal... Fulvestrant (Faslodex®) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen. The downregulation of cellular levels of the ER protein results in complete abrogation of estrogen-sensitive gene transcription. This distinct mechanism of action ensures a lack of cross resistance with other hormonal agents and, in contrast to tamoxifen, fulvestrant has no known estrogen-agonist effects. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Spotlight on fulvestrant in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy

Loading next page...
 
/lp/springer-journals/spotlight-on-fulvestrant-in-hormone-receptor-positive-metastatic-K8WiQ2A2eP
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403040-00008
Publisher site
See Article on Publisher Site

Abstract

Fulvestrant (Faslodex®) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen. The downregulation of cellular levels of the ER protein results in complete abrogation of estrogen-sensitive gene transcription. This distinct mechanism of action ensures a lack of cross resistance with other hormonal agents and, in contrast to tamoxifen, fulvestrant has no known estrogen-agonist effects.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References